Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.62B 1.42B 1.33B 1.22B 2.28B 155B 2.34B 15.74B 6.16B 76.73B 6.08B 5.95B 265B P/E 2026 *
-3.4x
P/E 2027 * -3.16x
Enterprise Value 1.18B 1.03B 964M 885M 1.66B 113B 1.7B 11.43B 4.47B 55.72B 4.41B 4.32B 193B EV / Sales 2026 *
18.2x
EV / Sales 2027 * 15.9x
Free-Float
96.67%
Yield 2026 *
-
Yield 2027 * -
1 day-3.44%
1 week-3.57%
Current month-19.07%
1 month-15.62%
3 months-12.90%
6 months-33.56%
Current year-27.38%
1 week 2.86
Extreme 2.86
3.13
1 month 2.84
Extreme 2.84
4.09
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
32.65
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Sell

Founder

-40,000 0.0076%
7/1/26 Free

Founder

3,747 0.0007%
7/1/26 Free

Director

5,109 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%-3.57%-52.93%-77.36% 1.62B
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.77%-1.39%+28.38%+141.32% 23.88B
Weighted average by Cap. +0.28%-0.75%+35.35%+129.21%

Financials

2026 *2027 *
Net sales 64.74M 56.88M 53.1M 48.73M 91.22M 6.2B 93.47M 630M 246M 3.07B 243M 238M 10.61B 83.76M 73.6M 68.7M 63.05M 118M 8.02B 121M 815M 319M 3.97B 314M 308M 13.72B
Net income -453M -398M -372M -341M -639M -43.41B -654M -4.41B -1.72B -21.48B -1.7B -1.66B -74.26B -525M -461M -431M -395M -740M -50.28B -758M -5.11B -2B -24.88B -1.97B -1.93B -86.01B
Net Debt -443M -390M -364M -334M -625M -42.46B -640M -4.31B -1.69B -21.01B -1.66B -1.63B -72.63B -285M -251M -234M -215M -402M -27.33B -412M -2.77B -1.09B -13.52B -1.07B -1.05B -46.75B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-07-29 US$2.970 -2.62% 17,870,010
26-07-28 US$3.050 +1.33% 24,398,105
26-07-27 US$3.010 +1.69% 21,724,275
26-07-24 US$2.960 -1.66% 16,530,380
26-07-23 US$3.010 +1.01% 18,832,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.955USD
Average target price
7.250USD
Spread / Average Target
+145.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock